Prostate Stem Cell Antigen Single Nucleotide Polymorphisms Influence Risk of Estrogen Receptor Negative Breast Cancer in Korean Females |
Kim, Sook-Young
(Cancer Genomics Branch, National Cancer Center)
Yoo, Jae-Young (Cancer Genomics Branch, National Cancer Center) Shin, Ae-Sun (Molecular Epidemiology Branch, National Cancer Center) Kim, Yeon-Ju (Cancer Early Detection Branch, National Cancer Center) Lee, Eun-Sook (Convergence Technology Division, National Cancer Center) Lee, Yeon-Su (Cancer Genomics Branch, National Cancer Center) |
1 | Wiechec E, Hansen LL (2009). The effect of genetic variability on drug response in conventional breast cancer treatment. Eur J Pharmacol, 625, 122-30. DOI |
2 | Williams C, Brunskill S, Altman D, et al. (2006). Costeffectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess, 10, iii-iv, ix-xi, 1-204. |
3 | Wu X, Ye Y, Kiemeney LA, et al. (2009). Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet, 41, 991-5. DOI |
4 | Yang X, Lippman ME (1999). BRCA1 and BRCA2 in breast cancer. Breast Cancer Res Treat, 54, 1-10. DOI |
5 | Yeager M, Xiao N, Hayes RB, et al. (2008). Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum Genet, 124, 161-70. DOI |
6 | Offit K, Robson ME (2010). New pharmacogenomic paradigm in breast cancer treatment. J Clin Oncol, 28, 4665-6. DOI |
7 | Onay VU, Briollais L, Knight JA, et al. (2006). SNP-SNP interactions in breast cancer susceptibility. BMC Cancer, 6, 114. DOI |
8 | Orlando L, Schiavone P, Fedele P, et al. (2010). Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev, 36 Suppl 3, S67-71. DOI |
9 | Ozet A, Yavuz AA, Komurcu S, et al. (2000). Bilateral male breast cancer and prostate cancer: a case report. Jpn J Clin Oncol, 30, 188-90. DOI |
10 | Raff AB, Gray A, Kast WM (2009). Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett, 277, 126-32. DOI |
11 | Reiter RE, Gu Z, Watabe T, et al. (1998). Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A, 95, 1735-40. DOI |
12 | Rochefort H, Glondu M, Sahla ME, et al. (2003). How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer, 10, 261-6. DOI |
13 | Thomas G, Jacobs KB, Kraft P, et al. (2009). A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet, 41, 579-84. DOI |
14 | Rugo HS (2008). The breast cancer continuum in hormonereceptor- positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol, 19, 16-27. DOI |
15 | Sakamoto H, Yoshimura K, Saeki N, et al (2008). Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet, 40, 730-40. DOI |
16 | Smith LF (2007). Palpable cancer of the breast and negative mammography: the ongoing dilemma. J Surg Oncol, 96, 451-2. DOI |
17 | Uray IP, Brown PH (2011). Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res, 188, 147-62. |
18 | Garcia-Closas M, Chanock S (2008). Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res, 14, 8000-9. DOI |
19 | Gluz O, Liedtke C, Gottschalk N, et al. (2009). Triple-negative breast cancer--current status and future directions. Ann Oncol, 20, 1913-27. DOI |
20 | Habel LA, Capra AM, Oestreicher N, et al. (2007). Mammographic density in a multiethnic cohort. Menopause, 14, 891-9. DOI |
21 | Han JS, Cao D, Molberg KH, et al. (2011). Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triplenegative breast carcinomas, and high expression of Ki-67 but not p53 is significantly associated with axillary nodal metastasis in triple-negative and high-grade non-triplenegative breast carcinomas. Am J Clin Pathol, 135, 230-7. DOI |
22 | Imyanitov EN (2009). Gene polymorphisms, apoptotic capacity and cancer risk. Hum Genet, 125, 239-46. DOI |
23 | Lopez-Otin C, Diamandis EP (1998). Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev, 19, 365-96. DOI |
24 | Jung KW, Park S, Kong HJ, et al. (2011). Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat, 43, 1-11. DOI |
25 | Kim BK, Lee JW, Park PJ, et al. (2009). The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res, 11, R22. DOI |
26 | Li J, Humphreys K, Heikkinen T, et al. (2010). A combined analysis of genome-wide association studies in breast cancer. Breast Cancer Res Treat. |
27 | Matera L (2010). The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. Cancer Treat Rev, 36, 131-41. DOI |
28 | Matsuo K, Tajima K, Suzuki T, et al. (2009). Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. Int J Cancer, 125, 1961-4. DOI |
29 | Berndt SI, Potter JD, Hazra A, et al. (2008). Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. Hum Mol Genet, 17, 2665-72. DOI |
30 | Buck MB, Fritz P, Dippon J, et al. (2004). Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res, 10, 491-8. DOI |
31 | Chen JQ, Brown TR, Russo J (2009). Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta, 1793, 1128-43. DOI |
32 | Chu LW, Meyer TE, Li Q, et al. (2010). Association between genetic variants in the 8q24 cancer risk regions and circulating levels of androgens and sex hormone-binding globulin. Cancer Epidemiol Biomarkers Prev, 19, 1848- 54. DOI |
33 | Cianfrocca M, Gradishar W (2009). New molecular classifications of breast cancer. CA Cancer J Clin, 59, 303-13. DOI |
34 | Coffey DS (2001). Similarities of prostate and breast cancer: Evolution, diet, and estrogens. Urology, 57, 31-8. DOI |
35 | Czajka-Oraniec I, Simpson ER (2010). Aromatase research and its clinical significance. Endokrynol Pol, 61, 126-34. |
36 | Ferlay J, Shin HR, Bray F, et al. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. DOI |
37 | Fletcher O, Johnson N, Gibson L, et al. (2008). Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev, 17, 702-5. DOI |
38 | Frasor J, Danes JM, Komm B, et al. (2003). Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology, 144, 4562-74. DOI |
39 | AleAhmad S, Casey G, Sweeney P, et al (2009). Prostate stem cell antigen DNA vaccination breaks tolerance to selfantigen and inhibits prostate cancer growth. Mol Ther, 17, 1101-8. DOI |
40 | Ahn SH (2004). Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg, 139, 27-30, discussion 1. DOI |
41 | Benson JR, Jatoi I, Keisch M, et al. (2009). Early breast cancer. Lancet, 373, 1463-79. DOI |